<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9">
<url>
<loc>https://mrdwatch.com/</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/about</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/privacy</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/editorial-policy</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/disclosures</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/subscribe</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/patients</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/patients/what-your-result-means</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/learn</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/learn/mrd</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/learn/utdna</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/learn/videos</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/learn/assay-sensitivity</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/learn/tissue-free-vs-tumor-informed</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/evidence</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/mced</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/publications</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/meetings</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/meetings/abstracts</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/meetings/education</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/cancer</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/trials</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/how-mrd</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/submit</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/sponsor</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/search</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/cancer/gu</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/cancer/gi</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/cancer/breast</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/cancer/lung</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/cancer/heme</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/cancer/gynecologic</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/cancer/head-neck</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/cancer/melanoma</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/cancer/other</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/cancer/gu/bladder</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/cancer/gu/kidney</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/cancer/gu/prostate</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/cancer/gu/penile</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/cancer/gu/germ-cell</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/cancer/gu/multiple</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/cancer/gi/colorectal</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/cancer/gi/gastroesophageal</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/cancer/gi/pancreatic</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/cancer/gi/liver</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/cancer/gi/biliary</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/cancer/heme/myeloma</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/cancer/heme/all</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/cancer/heme/cll</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/cancer/heme/aml</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/cancer/heme/lymphoma</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/tag/biomarkers</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/tag/trials</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/tag/fda</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/tag/conference</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/tag/guidelines</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/tag/tumor-informed</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/tag/reimbursement</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/janjigian-diaz-ann-oncol-2026</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/trap-ctdna-sbrt-prostate</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/nct07932067-upmc-hnscc-lymphdetect-sdf</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/pdac-tumor-informed-ctdna-metaanalysis-01629</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/ann-surg-oncol-crpm-ctdna-20869</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/nct07823322-nexera-204-incyte-natera</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/nct07930182-moffitt-melanoma-haystack</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/nct07927998-pacer-msk-anal-signatera</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/illumina-duplex-wgs-mrd-research-workflow</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/mibc-ctdna-adoption-esmo-open-108619</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/natera-sitc-2026-signatera-1l-io</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/billiontoone-northstar-clear-launch-date</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/khorasanchi-meng-cancers-2026</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/jlb-100540-her2-mbc-methylation-ctdna</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/precision-esmo-open-108622</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/her2-cr-esmo-open-108639</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/volga-esmo-2026-lba2</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/esmo-2026-prompt-ctdna-hrr</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/cho-khalil-jtocrr-2026</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/jama-tissue-free-tnbc-2026</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/fda-pluvicto-psma-mhspc</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/timber-ctdna-mibc-opens</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/fda-capivasertib-pten-prostate</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/altair-crc</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/nct07401316-germ-cell-ctdna-opens</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/foundationone-hrr-talazoparib-enzalutamide</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/nccn-psma-pet-tracer-table</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/nccn-brca2-niraparib-mhspc</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/nccn-nccrcc-genomic-testing</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/ovarian-ctdna-sll-asco-2026</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/asco-2026-signatera-ev-pembro</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/fda-atezolizumab-ctdna-mrd</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/atellica-free-psa-ii</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/asco-gu-2026-testicular-ctdna-surveillance</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/asco-gu-2026-ctdna-primary-rplnd</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/monstar-screen-3-rcc-mrd</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/asco-gu-2026-signatera-mibc-surveillance</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/asco-gu-2026-gct-ctdna-marker-negative</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/asco-gu-2026-comrade-ctdna</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/myeloma-mrd-fda-draft-2026</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/signatera-postnephrectomy-rcc</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/moldx-ovarian-2026</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/moldx-head-neck-2026</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/moldx-crc-assays-2026</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/moldx-nsclc-2026</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/esmo-prostate-guideline-hrr</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/moldx-breast-2026</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/moldx-bladder-2026</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/moldx-ici-monitoring-2026</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/tracex-cell-2025</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/dynamic-iii-persistent-ctdna</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/imvigor011-nejm</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/dynamic-iii-colon</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/checkmate-915-ctdna-2025</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/adapt-mrd-pancreas-opens</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/neocircle-asco-2025</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/monstar-screen-3-asco-2025</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/monstar-gastroesophageal-enrollment</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/pancreatic-mrd-asco-2025</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/adult-all-mrd-blood-advances-2025</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/tracex-preop-below-80ppm</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/tracex-preop-natmed-2025</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/bespoke-crc-asco-gi-2025</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/alpha-correct-stage-iii-crc</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/zest-breast-ctdna</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/detection-2-melanoma</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/impower010-ctdna-esmo-2024</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/impower010-ctdna-clearance</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/analytical-validation-of-next-personal-an-ultra-sensitive-person-38484152</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/ultrasensitive-detection-and-tracking-of-circulating-tumor-dna-t-40500687</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/longitudinal-ctdna-monitoring-for-postsurgical-disease-surveilla-41632449</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/longitudinal-testing-of-circulating-tumor-dna-in-patients-with-m-39693589</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-in-high-risk-stage-ii-iii-cutaneous-melano-40146490</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/longitudinal-tumor-informed-ctdna-monitoring-for-recurrence-and-41928167</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/bespoke-ctdna-for-longitudinal-detection-of-molecular-residual-d-39549683</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/personalized-ctdna-detection-and-genomic-profiling-in-the-neorhe-41350280</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/predictive-role-of-circulating-tumor-dna-in-stage-iii-colon-canc-41343176</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-using-a-plasma-only-assay-predicts-surviva-40386606</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/highly-accurate-detection-of-circulating-tumor-dna-for-monitorin-42624249</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/association-of-tumor-informed-circulating-tumor-dna-detectabilit-39013741</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/rapid-clearance-profile-of-plasma-circulating-tumor-hpv-type-16-31088830</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/plasma-circulating-tumor-hpv-dna-for-the-surveillance-of-cancer-32017652</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/detectable-postoperative-circulating-tumor-human-papillomavirus-35157995</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/postoperative-human-papilloma-virus-circulating-tumor-dna-guided-41043558</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/performance-and-cost-effectiveness-of-tumor-tissue-modified-vira-42605455</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/ultrasensitive-ctdna-detection-for-preoperative-disease-stratifi-39806071</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/longitudinal-ultrasensitive-ctdna-monitoring-for-high-resolution-41205598</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/monitoring-treatment-response-using-an-ultra-sensitive-ctdna-ass-41872254</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/whole-genome-sequencing-powered-ctdna-sequencing-for-breast-canc-39914664</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/ultrasensitive-ctdna-monitoring-reveals-early-predictors-of-immu-41580469</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/broad-utility-of-ultrasensitive-analysis-of-ctdna-dynamics-acros-41400436</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-dynamics-in-patients-with-hormone-receptor-42617422</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/ultrasensitive-circulating-tumor-dna-detection-improves-prognost-42531804</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/neoadjuvant-paclitaxel-trastuzumab-and-pertuzumab-for-stage-ii-t-42348190</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/the-pathologic-response-evaluation-and-detection-in-circulating-41805422</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/results-of-the-c-trak-tn-trial-a-clinical-trial-utilising-ctdna-36423745</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/ultrasensitive-detection-and-monitoring-of-circulating-tumor-dna-39785866</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-in-neoadjuvant-treated-breast-cancer-refle-33232761</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/clinical-significance-and-biology-of-circulating-tumor-dna-in-hi-37146605</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/personalized-detection-of-circulating-tumor-dna-antedates-breast-30992300</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-based-molecular-residual-disease-detection-36869646</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/personalized-circulating-tumor-dna-assay-to-assess-long-term-cli-41375005</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/prospective-assessment-of-circulating-tumor-dna-in-patients-with-39402032</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/genomic-analysis-of-circulating-tumor-dna-using-a-melanoma-speci-30731208</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-in-conjunctival-melanoma-landscape-and-sur-39424026</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/design-and-testing-of-a-custom-melanoma-next-generation-sequenci-32785074</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/preoperative-circulating-tumor-hpv-dna-and-oropharyngeal-squamou-38573644</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/postoperative-cthpvdna-kinetics-in-patients-with-hpv-related-oro-40367049</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/determinants-of-circulating-tumor-hpv-dna-in-surgically-treated-41926134</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/double-trouble-synchronous-and-metachronous-primaries-confound-c-37080924</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-hpv-dna-in-the-management-of-hpv-positive-orop-38979763</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/patient-experiences-with-cthpvdna-guided-surveillance-for-hpv-po-42955024</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/the-landscape-of-circulating-tumor-hpv-dna-and-ttmv-hpvdna-for-s-39095868</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-analysis-guiding-adjuvant-therapy-in-stage-35657320</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/molecular-residual-disease-and-efficacy-of-adjuvant-chemotherapy-36646802</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/a-tumor-na-ve-ctdna-assay-detects-minimal-residual-disease-in-re-39513962</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/survival-benefit-of-adjuvant-chemotherapy-based-on-molecular-res-39293512</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/validation-of-a-methylation-based-tissue-free-mrd-assay-in-color-41555007</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/ctdna-guided-adjuvant-atezolizumab-in-muscle-invasive-bladder-ca-41124204</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/updated-overall-survival-by-circulating-tumor-dna-status-from-th-37500339</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/tracking-early-lung-cancer-metastatic-dissemination-in-tracerx-u-37055640</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/individualized-tumor-informed-circulating-tumor-dna-analysis-for-37683638</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/ultrasensitive-circulating-tumor-dna-pilot-study-distinguishes-c-37027813</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/residual-circulating-tumor-dna-after-adjuvant-chemotherapy-effec-37837629</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-predicts-recurrence-and-survival-in-patien-39369091</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-and-tissue-testing-for-pancreatobiliary-tu-40938601</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/daratumumab-carfilzomib-lenalidomide-and-dexamethasone-with-mini-34898239</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/minimal-residual-disease-response-adapted-therapy-in-newly-diagn-37776872</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/analytical-evaluation-of-the-clonoseq-assay-for-establishing-mea-32605647</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/next-generation-sequencing-based-mrd-in-adults-with-all-undergoi-37196642</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/multiparameter-flow-cytometry-and-clonoseq-correlation-to-evalua-38175444</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/ctdna-guiding-adjuvant-immunotherapy-in-urothelial-carcinoma-34135506</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-guided-adjuvant-therapy-in-locally-advance-41115959</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/mutation-tracking-in-circulating-tumor-dna-predicts-relapse-in-e-26311728</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-in-stage-iii-colorectal-cancer-beyond-mini-34625408</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/adjuvant-nivolumab-versus-placebo-for-high-risk-muscle-invasive-41110694</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/post-adjuvant-chemotherapy-in-ctdna-positive-patients-with-resec-42260101</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-guided-de-escalation-or-escalation-of-adju-42736431</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-in-oligoprogressive-prostate-cancer-treate-43013307</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/risk-stratification-by-circulating-tumor-dna-based-pretreatment-42950585</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/real-world-adoption-of-circulating-tumor-dna-testing-and-adjuvan-42994396</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/perioperative-circulating-tumor-dna-dynamics-in-patients-undergo-43009710</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/methylation-based-circulating-tumor-dna-enables-molecular-detect-jlb-100540</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/ultra-sensitive-mrd-assessment-in-long-term-complete-responders-43014086</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/postoperative-tumor-informed-circulating-tumor-dna-status-for-mo-43013192</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/detection-of-occult-recurrence-using-circulating-tumor-tissue-mo-35576437</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/negative-predictive-value-of-circulating-tumor-tissue-modified-v-37566241</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/a-prospective-trial-of-biomarker-guided-surveillance-for-hpv-pos-39715483</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/performance-of-liquid-biopsy-for-diagnosis-and-surveillance-of-h-37422913</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/cell-free-hpv-dna-provides-an-accurate-and-rapid-diagnosis-of-hp-34857594</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/cell-free-human-papillomavirus-dna-kinetics-after-surgery-for-hu-35139236</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/personalized-ctdna-for-monitoring-disease-status-in-head-and-nec-38824449</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/liquid-biopsy-for-minimal-residual-disease-detection-in-head-and-35132238</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/personalized-ctdna-analysis-for-detection-of-residual-disease-an-41634365</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/tumor-agnostic-plasma-assay-for-circulating-tumor-dna-detects-mi-37879442</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/tumor-informed-ctdna-assay-to-predict-recurrence-in-locally-adva-40279884</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/ctdna-and-recurrence-risk-for-adjuvant-de-escalation-in-hpv-posi-40402484</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/detection-of-early-human-papillomavirus-associated-cancers-by-li-31485558</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/plasma-hpv-cell-free-dna-monitoring-in-advanced-hpv-associated-o-30010779</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/liquid-biopsies-with-circulating-plasma-hpv-dna-measurements-a-c-37477909</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/detection-of-circulating-tumor-human-papillomavirus-dna-before-d-35262203</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-hpv-dna-for-surveillance-of-hpv-positive-oroph-37824111</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/early-postoperative-minimal-residual-disease-detection-with-maes-40392096</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/personalized-circulating-tumor-dna-dynamics-inform-survival-and-40846896</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-human-papillomavirus-dna-whole-genome-sequenci-40925715</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/quantitative-analysis-of-cell-free-epstein-barr-virus-dna-in-pla-10096545</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/quantitative-and-temporal-correlation-between-circulating-cell-f-10554016</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/quantification-of-plasma-epstein-barr-virus-dna-in-patients-with-15190138</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/analysis-of-plasma-epstein-barr-virus-dna-to-screen-for-nasophar-28792880</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/sequencing-based-counting-and-size-profiling-of-plasma-epstein-b-29760067</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/analysis-of-plasma-epstein-barr-virus-dna-in-nasopharyngeal-canc-29989858</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/dynamic-changes-of-post-radiotherapy-plasma-epstein-barr-virus-d-33692028</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/fragmentomics-profiling-and-quantification-of-plasma-epstein-bar-40054465</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/durvalumab-versus-placebo-with-chemoradiotherapy-for-locally-adv-38039991</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-hpv-dna-as-a-marker-for-early-detection-of-relapse-i-34210686</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/hpv-ctdna-detection-of-high-risk-hpv-types-during-chemoradiother-34022731</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-human-papillomavirus-dna-detected-using-droplet-digi-27917295</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-cell-free-dna-for-metastatic-cervical-cancer-detecti-28899967</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-cell-free-tumor-human-papillomavirus-dna-is-a-promis-35918201</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-hpv-cdna-in-the-blood-as-a-reliable-biomarker-for-ce-32027658</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/personalized-circulating-tumor-dna-biomarkers-dynamically-predic-26717006</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/exploratory-analysis-of-tp53-mutations-in-circulating-tumour-dna-27997533</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-monitoring-for-early-recurrence-detection-36117009</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/the-prognostic-value-of-tumor-informed-minimal-residual-disease-39579602</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/surgical-and-blood-based-minimal-residual-disease-in-patients-wi-40748258</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/ctdna-as-an-objective-marker-for-postoperative-residual-disease-40075633</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/multimodal-tumor-agnostic-ctdna-analysis-for-minimal-residual-di-41747586</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/prognostic-value-of-circulating-tumor-dna-for-minimal-residual-d-41895358</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-monitoring-in-ovarian-cancer-patients-rece-41252813</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/post-surgical-ctdna-based-molecular-residual-disease-detection-i-38262240</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/using-circulating-tumor-dna-based-molecular-residual-disease-det-40991886</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/high-sensitivity-mutation-analysis-of-cell-free-dna-for-disease-36007103</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/utility-of-circulating-tumor-dna-for-detection-and-monitoring-of-32785174</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/prognostic-value-of-perioperative-circulating-tumor-dna-in-endom-41420893</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/kim-1-and-circulating-tumor-dna-are-prognostic-markers-for-oligo-41765697</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/metastasis-directed-radiotherapy-without-systemic-therapy-for-ol-40915303</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/addition-of-metastasis-directed-therapy-to-standard-of-care-for-42142259</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/immune-and-circulating-tumor-dna-profiling-after-radiation-treat-31678224</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/neoadjuvant-botensilimab-with-or-without-balstilimab-in-pmmr-and-42972108</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/5-year-outcomes-of-chemotherapy-de-escalation-in-her2-positive-e-42957778</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/talazoparib-plus-enzalutamide-versus-placebo-plus-enzalutamide-i-42950862</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/ctdna-clearance-and-outcomes-for-resectable-lung-cancer-from-neo-42927884</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/lymph-node-targeted-mkras-specific-amphiphile-vaccine-in-pancrea-42919966</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/neoadjuvant-nivolumab-plus-gemcitabine-cisplatin-followed-by-pos-42918420</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/disease-free-survival-and-overall-survival-after-neoadjuvant-imm-42906564</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/postresection-urinary-tumor-dna-refines-residual-disease-assessm-42981539</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/adjuvant-mfolfoxiri-after-curative-intent-resection-of-oligometa-42981165</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/comparative-analysis-of-ctdna-mrd-and-mvi-in-predicting-postoper-42955557</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/prospective-circulating-tumour-dna-surveillance-in-patients-with-42946309</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/neoadjuvant-durvalumab-plus-chemotherapy-in-resectable-or-border-42934326</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/serial-circulating-tumour-dna-monitoring-in-first-line-advanced-42905748</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/hpv16-circulating-tumour-dna-for-prognostic-stratification-and-p-42933086</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/tumor-informed-circulating-tumor-dna-monitoring-for-predicting-o-42999361</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/histone-modifications-define-distinct-nucleosome-positions-in-ce-42990193</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/association-of-tumor-informed-circulating-tumor-dna-dynamics-wit-42947038</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-guided-therapeutic-strategies-for-metastat-42962410</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/postoperative-ctdna-could-potentially-spare-patients-from-unnece-42964065</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/real-world-utilization-of-tissue-free-ctdna-mrd-testing-in-non-s-42938831</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/prognostic-vs-predictive-value-of-ctdna-for-chemotherapy-plannin-42986614</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/prognostic-vs-predictive-value-of-ctdna-for-chemotherapy-plannin-42986612</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/ultrasensitive-ctdna-assay-lowers-the-detection-floor-in-esophag-42975193</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/earlier-is-not-necessarily-actionable-the-clinical-dilemma-of-ci-42956181</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/consensus-and-controversy-of-liquid-biopsy-using-circulating-tum-42964788</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/attitudes-of-cancer-patients-toward-ctdna-based-liquid-biopsy-fo-42905048</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/abstract-3845-enhancing-mrd-detection-through-an-ultrasensitive-10-1158-1538-7445-am2026</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/safety-and-performance-results-from-pathfinder-2-a-registrationa-10-1200-jco-2026-44-17-s</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/nhs-galleri-primary-results-from-a-randomised-controlled-trial-t-10-1200-jco-2026-44-17-s</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/patient-reported-outcomes-from-imvigor011-a-phase-3-study-of-cir-10-1200-jco-2026-44-16-s</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/ctdna-analysis-in-participants-with-renal-cell-carcinoma-treated-10-1200-jco-2026-44-16-s</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-ctdna-to-guide-response-adapted-bladder-pr-10-1200-jco-2026-44-7-su</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/whole-genome-based-ultrasensitive-circulating-tumor-dna-clearanc-10-1200-jco-2026-44-7-su</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/urinary-tumor-dna-utdna-and-circulating-tumor-dna-ctdna-in-patie-10-1200-jco-2026-44-7-su</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-ct-dna-guided-adjuvant-atezolizumab-atezo-in-m-10-1200-jco-2026-44-7-su</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/use-of-ultra-sensitive-whole-genome-circulating-tumor-dna-detect-10-1200-jco-2026-44-7-su</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-kim-1-and-ctdna-as-prognostic-markers-in-oligometast-tang-kcompass-ascogu-202</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/416o-smart-on-treatment-ctdna-dynamics-predicts-response-and-pro-esmo-2026-416o-esmo-brea</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/mute-seq-enables-efficient-single-digit-ppm-tumor-informed-ctdna-esmo-2026-2446p-esmo-con</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/clinical-utility-of-ultra-sensitive-ctdna-mrd-monitoring-in-adva-esmo-2026-2728ep-esmo-co</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/novel-error-corrected-tumor-informed-whole-genome-sequencing-ctd-esmo-2026-4273p-esmo-con</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/postoperative-tav16-ctdna-detects-molecular-residual-disease-and-esmo-2026-3192ep-esmo-co</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/ctdna-status-and-adjuvant-chemotherapy-after-resection-of-colore-esmo-2026-8o-esmo-gastro</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/optimizing-oligometastatic-disease-management-with-circulating-t-sherry-estro-2026-846</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/phase-2-trial-of-metastasis-directed-radiotherapy-without-system-tang-mrws-aacr-2025-ct13</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-and-late-recurrence-in-high-risk-hormone-r-10-1200-jco-2025-43-16-s</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/ctdna-guided-adjuvant-chemotherapy-escalation-in-stage-iii-colon-10-1200-jco-2025-43-16-s</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-ctdna-in-patients-with-muscle-invasive-bla-10-1200-jco-2025-43-16-s</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/association-of-tumor-informed-ctdna-based-molecular-residual-dis-10-1200-jco-2025-43-16-s</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/association-of-post-surgical-mrd-status-with-neoadjuvant-ctdna-d-10-1200-jco-2025-43-16-s</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/longitudinal-ctdna-monitoring-for-post-surgical-molecular-residu-10-1200-jco-2025-43-16-s</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/ultrasensitive-detection-and-tracking-of-circulating-tumor-dna-c-mayadev-asco-2025-5502</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-for-detection-of-molecular-residual-diseas-10-1200-jco-2025-43-4-su</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/a-randomized-double-blind-phase-iii-study-comparing-trifluridine-10-1200-jco-2025-43-4-su</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/lba68-cctg-br-31-adjuvant-durvalumab-d-in-resected-non-small-cel-10-1016-j-annonc-2025-09</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/heroes-de-escalation-of-anti-her2-therapies-in-her2-positive-met-esmo-2025-620tip-esmo-co</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/the-survive-heroes-study-targeting-molecular-relapse-in-breast-c-esmo-2025-464etip-esmo-c</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/molecular-residual-disease-mrd-analysis-from-the-laura-study-of-esmo-2025-1817mo-esmo-co</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/safety-and-performance-of-a-multi-cancer-early-detection-mced-te-esmo-2025-lba64-esmo-con</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/3068o-adjuvant-nivolumab-vs-placebo-for-high-risk-muscle-invasiv-10-1016-j-annonc-2025-08</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/lba8-imvigor011-a-phase-iii-trial-of-circulating-tumour-ct-dna-g-10-1016-j-annonc-2025-09</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/lba9-ctdna-guided-adjuvant-chemotherapy-de-escalation-in-stage-i-10-1016-j-annonc-2025-09</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/723o-post-surgical-liquid-biopsy-guided-treatment-of-stage-iii-a-10-1016-j-annonc-2025-08</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/3o-association-of-ctdna-clearance-with-disease-free-survival-saf-10-1016-j-annonc-2025-05</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/lba1-dynamic-circulating-tumor-dna-methylation-monitoring-guidin-10-1016-j-annonc-2025-05</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/abstract-rf3-05-tissue-free-circulating-tumour-dna-detection-in-10-1158-1557-3265-sabcs2</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/phase-2-trial-of-metastasis-directed-radiotherapy-without-system-tang-mrws-oncologist-202</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/ultra-sensitive-ctdna-mutation-tracking-to-identify-molecular-re-10-1200-jco-2024-42-16-s</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/the-potential-role-of-serial-circulating-tumor-dna-ctdna-testing-10-1200-jco-2024-42-16-s</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-analysis-guiding-adjuvant-therapy-in-stage-10-1200-jco-2024-42-16-s</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/molecular-residual-disease-mrd-analysis-from-the-adaura-trial-of-10-1200-jco-2024-42-16-s</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/comparison-of-primary-versus-metastatic-tumor-tissue-sources-whe-seo-asco-2024-3039</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-analysis-informing-adjuvant-chemotherapy-i-10-1200-jco-2024-42-3-su</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-ctdna-for-informing-adjuvant-chemotherapy-10-1200-jco-2024-42-3-su</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-ctdna-dynamics-in-patients-with-colorectal-10-1200-jco-2024-42-3-su</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/phase-ii-results-of-circulating-tumor-dna-as-a-predictive-biomar-10-1200-jco-2024-42-3-su</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/longitudinal-circulating-tumor-dna-monitoring-for-detection-of-m-10-1200-jco-2024-42-4-su</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/impower010-ctdna-status-and-5-year-disease-free-survival-follow-esmo-2024-1211p-esmo-con</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/association-of-ctdna-based-mrd-detection-and-mrd-clearance-with-esmo-2024-553p-esmo-cong</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/association-between-copy-number-aberration-and-ctdna-mrd-in-colo-esmo-2024-555p-esmo-cong</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/survival-benefit-of-adjuvant-chemotherapy-based-on-mrd-detection-esmo-2024-558p-esmo-cong</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/abstract-gs3-01-circulating-tumor-dna-surveillance-in-zest-a-ran-10-1158-1557-3265-sabcs2</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/minimal-residual-disease-by-circulating-tumor-dna-as-a-biomarker-10-1200-jco-2023-41-17-s</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/longitudinal-circulating-tumor-dna-monitoring-for-detection-of-m-10-1200-jco-2023-41-16-s</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-dynamics-as-an-early-predictor-of-recurren-10-1200-jco-2023-41-16-s</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/association-of-tumor-informed-minimal-residual-disease-mrd-with-10-1200-jco-2023-41-16-s</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/clinical-evaluation-of-cancer-signal-origin-prediction-and-diagn-10-1200-jco-2023-41-16-s</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/longitudinal-detection-of-circulating-tumor-dna-in-patients-with-10-1200-jco-2023-41-6-su</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/lba28-the-pegasus-trial-post-surgical-liquid-biopsy-guided-treat-10-1016-j-annonc-2023-10</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/guide-mrd-a-consortium-guiding-multimodal-therapies-against-mini-esmo-2023-237tip-esmo-co</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/adjuvant-chemotherapy-guided-by-circulating-tumor-dna-analysis-i-10-1200-jco-2022-40-17-s</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/liquid-biopsy-for-minimal-residual-disease-detection-in-head-and-10-1200-jco-2022-40-16-s</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-ctdna-and-late-recurrence-in-high-risk-hor-10-1200-jco-2022-40-16-s</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/association-of-circulating-tumor-dna-dynamics-with-clinical-outc-10-1200-jco-2022-40-4-su</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/molecular-residual-disease-mrd-detection-with-a-tissue-comprehen-10-1200-jco-2022-40-6-su</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/risk-profiling-of-patients-with-previously-untreated-diffuse-lar-10-1182-blood-2022-15755</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/minimal-residual-disease-guided-adjuvant-tislelizumab-after-adju-esmo-2022-304tip-esmo-as</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/a-tumor-informed-hybrid-capture-ctdna-assay-for-mrd-detection-in-esmo-2022-381p-esmo-cong</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/tumour-na-ve-ctdna-analysis-in-resected-colorectal-cancer-in-the-esmo-2022-380p-esmo-cong</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/abstract-pd5-03-pd5-03-comparison-of-a-personalized-sequencing-a-10-1158-1538-7445-sabcs2</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/a-prespecified-interim-analysis-of-the-pathfinder-study-performa-10-1200-jco-2021-39-15-s</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/phase-ii-study-of-anti-egfr-rechallenge-therapy-with-panitumumab-10-1200-jco-2021-39-15-s</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/residual-ctdna-after-treatment-predicts-early-relapse-in-patient-10-1200-jco-2021-39-15-s</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/personalized-ctdna-analysis-to-detect-minimal-residual-disease-a-10-1200-jco-2021-39-15-s</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/leveraging-phased-variants-for-personalized-minimal-residual-dis-10-1200-jco-2021-39-15-s</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/2o-impower010-biomarkers-of-disease-free-survival-dfs-in-a-phase-10-1016-j-annonc-2021-10</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/abstract-gs3-06-primary-results-of-the-ctrak-tn-trial-a-clinical-10-1158-1538-7445-sabcs2</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/enhancing-mrd-detection-through-an-ultrasensitive-ctdna-test-ins-aacr-2026-3845</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/clinical-utility-of-ultrasensitive-ctdna-detection-across-the-re-kcrs26-41</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/use-of-ultra-sensitive-whole-genome-circulating-tumor-dna-detect-asco-gu-2026-516</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/whole-genome-based-ultrasensitive-circulating-tumor-dna-clearanc-asco-gu-2026-866</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/a-trial-of-adjuvant-chemotherapy-in-nasopharyngeal-carcinoma-pat-nct00370890</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/surgery-and-or-radiation-therapy-or-standard-therapy-and-or-clin-nct01725165</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/prospective-nasopharyngeal-carcinoma-screening-using-plasma-epst-nct02063399</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/individualized-treatment-in-treating-patients-with-stage-ii-ivb-nct02135042</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/monitoring-plasma-tumor-dna-in-early-stage-breast-cancer-nct02743910</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/evaluation-of-de-escalated-adjuvant-radiation-therapy-for-human-nct02908477</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/c-trak-tn-ctdna-surveillance-to-trigger-pembrolizumab-in-early-t-nct03145961</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/stereotactic-body-radiation-therapy-in-treating-patients-with-ol-nct03575611</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/systemic-therapy-with-or-without-local-consolidative-therapy-in-nct03599765</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/study-of-durvalumab-with-chemoradiotherapy-for-women-with-locall-nct03830866</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/cobra-ctdna-as-a-predictive-biomarker-for-adjuvant-chemotherapy-nct04068103</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/tombola-atezolizumab-at-ctdna-relapse-after-radical-cystectomy-nct04138628</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/pegasus-liquid-biopsy-guided-adjuvant-therapy-for-stage-iii-and-nct04259944</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/bespoke-crc-observational-study-of-tumor-informed-ctdna-after-co-nct04264702</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/atezolizumab-plus-sacituzumab-govitecan-to-prevent-recurrence-in-nct04434040</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/altair-trifluridine-tipiracil-versus-placebo-when-ctdna-becomes-nct04457297</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/mermaid-2-durvalumab-versus-placebo-for-mrd-positive-stage-ii-to-nct04642469</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/imvigor011-adjuvant-atezolizumab-versus-placebo-for-ctdna-positi-nct04660344</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/venetoclax-rituximab-and-ibrutinib-with-treatment-adapted-to-und-nct04758975</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/serial-ctdna-monitoring-during-adjuvant-capecitabine-in-early-tr-nct04768426</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/risk-adapted-therapy-in-hpv-oropharyngeal-cancer-using-circulati-nct04900623</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/zest-niraparib-versus-placebo-for-ctdna-positive-breast-cancer-a-nct04915755</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/early-detection-of-molecular-relapse-with-ctdna-tracking-and-tre-nct04985266</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/oracle-observational-ctdna-surveillance-across-early-stage-solid-nct05059444</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/ctdna-for-recurrence-detection-in-high-risk-resected-melanoma-nct05079113</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/minimal-residual-disease-guided-maintenance-with-belantamab-mafo-nct05091372</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulate-us-adjuvant-chemotherapy-assigned-from-postoperative-c-nct05174169</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/predicting-the-risk-of-ovarian-cancer-recurrence-using-circulati-nct05212779</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/a-study-on-using-cell-free-tumor-dna-ctdna-testing-to-decide-whe-nct05307939</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/kadcyla-and-neratinib-for-interception-of-her2-positive-breast-c-nct05388149</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/molecular-residual-disease-interception-in-locoregionally-advanc-nct05414032</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/de-escalated-adjuvant-and-definitive-radiation-therapy-informed-nct05541016</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/modulation-therapy-for-locally-advanced-npc-based-on-plasma-ebv-nct05628922</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-to-guide-changes-in-standard-of-care-chemo-nct05770531</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/postoperative-adjuvant-therapy-for-cervical-cancer-based-on-mini-nct05872724</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/memory-ctdna-methylation-for-surveillance-after-kidney-cancer-su-nct05917106</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/modern-mrd-guided-adjuvant-nivolumab-with-or-without-relatlimab-nct05987241</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/a-randomized-trial-of-maintenance-systemic-therapy-after-radiati-nct06004336</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/mrd-gate-rcc-observation-instead-of-adjuvant-pembrolizumab-when-nct06005818</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/glofitamab-in-a-response-adapted-approach-using-interim-fdg-pet-nct06050694</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/sequential-ctdna-profiling-in-advanced-ovarian-cancer-nct06071286</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/adaptive-de-intensified-radiotherapy-using-circulating-tumor-dna-nct06323460</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/using-circulating-tumor-dna-to-risk-adapt-post-operative-therapy-nct06445114</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/tirzepatide-weight-loss-for-mrd-positive-early-breast-cancer-nct06517212</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/trastuzumab-deruxtecan-versus-standard-therapy-for-molecular-rel-nct06643585</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/mosunetuzumab-consolidation-for-older-patients-with-dlbcl-and-de-nct06828991</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/cthpvdna-in-hpv-positive-squamous-cell-carcinoma-of-the-orophary-nct06915038</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/adapt-mrd-ctdna-guided-adjuvant-therapy-after-resection-of-pancr-nct06966440</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/ctdna-guided-de-escalation-of-adjuvant-chemotherapy-with-dalpici-nct06970912</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/ctdna-monitoring-in-hepatocellular-carcinoma-and-metastatic-colo-nct07001085</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/molecular-residual-disease-assessment-in-early-stage-breast-canc-nct07025785</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/predict-rd-ctdna-surveillance-in-tnbc-with-residual-disease-nct07069595</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/imlunestrant-and-abemaciclib-for-estrogen-receptor-positive-brea-nct07191717</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/mirade-ctdna-minimal-residual-disease-after-prostatectomy-for-hi-nct07334275</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/signatera-assessment-in-early-stage-endometrial-cancer-nct07339384</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/cdk4-6-inhibitors-with-endocrine-therapy-as-neoadjuvant-treatmen-nct07366112</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/ctdna-in-stage-i-ii-and-iii-germ-cell-tumors-nct07401316</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/herizon-breast-a-ctdna-guided-adaptive-study-of-sequential-anti-nct07459673</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/mrd-guided-maintenance-after-transplant-in-flt3-itd-acute-myeloi-nct07463651</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/t1g3r-1-ctdna-detectability-and-prognosis-in-t1-grade-3-bladder-nct07581496</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/capecitabine-in-er-positive-her2-negative-breast-cancer-with-mol-nct07631052</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/timber-tumor-informed-ctdna-and-recurrence-in-muscle-invasive-bl-nct07726602</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/a-study-to-evaluate-inca33890-in-the-treatment-of-circulating-tu-nct07823322</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/a-study-of-retifanlimab-after-chemoradiation-in-people-with-anal-nct07927998</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/adjuvant-neoadjuvant-immunotherapy-in-melanoma-based-on-serial-p-nct07930182</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-informed-adjuvant-therapy-for-intermediate-nct07932067</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/fda-oncologic-drugs-advisory-committee-vote-on-mrd-as-an-acceler-reg-odac-2024</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/minimal-residual-disease-and-complete-response-in-multiple-myelo-reg-fda-guidance-2026</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/fda-accelerated-approval-of-iberdomide-zenbexus-with-daratumumab-reg-iberdomide-2026</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/fda-authorizes-clonoseq-the-first-ngs-based-mrd-test-for-multipl-reg-clonoseq-2018</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/fda-expands-blinatumomab-blincyto-approval-to-mrd-positive-b-cel-reg-blinatumomab-mrd-201</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/international-myeloma-working-group-consensus-criteria-for-respo-kumar-imwg-2016</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/association-of-minimal-residual-disease-with-superior-survival-o-munshi-jamaoncol-2017</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/next-generation-flow-for-highly-sensitive-and-standardized-detec-flores-montero-2017</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/a-large-meta-analysis-establishes-the-role-of-mrd-negativity-in-munshi-bloodadv-2020</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/daratumumab-lenalidomide-bortezomib-and-dexamethasone-for-transp-voorhees-griffin-2020</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/daratumumab-carfilzomib-lenalidomide-and-dexamethasone-with-mini-costa-master-2022</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/minimal-residual-disease-response-adapted-therapy-in-newly-diagn-costa-master-final-2023</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/addition-of-isatuximab-to-lenalidomide-bortezomib-and-dexamethas-goldschmidt-hd7-2022</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/isatuximab-lenalidomide-bortezomib-and-dexamethasone-induction-t-mai-hd7-2025</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/daratumumab-bortezomib-lenalidomide-and-dexamethasone-for-multip-sonneveld-perseus-2024</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/evidence-meta-analysis-evaluating-minimal-residual-disease-as-an-landgren-evidence-2024</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/minimal-residual-disease-based-end-point-for-accelerated-assessm-shi-i2teamm-2025</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/isatuximab-carfilzomib-lenalidomide-and-dexamethasone-induction-perrot-midas-induction-2</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/measurable-residual-disease-guided-therapy-in-newly-diagnosed-my-perrot-midas-nejm-2025</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/discontinuation-of-maintenance-therapy-in-multiple-myeloma-guide-derman-mrd2stop-2024</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/daratumumab-bortezomib-thalidomide-dexamethasone-for-newly-diagn-corre-cassiopeia-mrd-202</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/daratumumab-plus-bortezomib-lenalidomide-and-dexamethasone-for-t-usmani-cepheus-2025</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/monitoring-minimal-residual-disease-in-patients-with-multiple-my-fan-easym-2024</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/comparison-of-easym-a-clonotypic-mass-spectrometry-assay-and-eur-zhao-easym-2025</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/swog-s1803-drammatic-daratumumab-lenalidomide-vs-lenalidomide-ma-trial-drammatic</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/daratumumab-in-transplant-ineligible-or-deferred-newly-diagnosed-zweegman-cepheus-mrd-202</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/blinatumomab-for-minimal-residual-disease-in-adults-with-b-cell-gokbuget-blast-2018</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/dasatinib-blinatumomab-for-ph-positive-acute-lymphoblastic-leuke-foa-dalba-2020</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/blinatumomab-for-mrd-negative-acute-lymphoblastic-leukemia-in-ad-litzow-e1910-2024</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/blinatumomab-in-standard-risk-b-cell-acute-lymphoblastic-leukemi-gupta-aall1731-2025</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/venetoclax-rituximab-in-relapsed-or-refractory-chronic-lymphocyt-seymour-murano-2018</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/fixed-duration-of-venetoclax-rituximab-in-relapsed-refractory-ch-kater-murano-mrd-2019</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/venetoclax-and-obinutuzumab-in-patients-with-cll-and-coexisting-fischer-cll14-2019</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/minimal-residual-disease-dynamics-after-venetoclax-obinutuzumab-alsawaf-cll14-mrd-2021</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/venetoclax-obinutuzumab-for-previously-untreated-chronic-lymphoc-alsawaf-cll14-6y-2024</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/ibrutinib-plus-venetoclax-for-first-line-treatment-of-chronic-ly-wierda-captivate-mrd-202</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/fixed-duration-ibrutinib-plus-venetoclax-for-first-line-treatmen-tam-captivate-fd-2022</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/chronic-lymphocytic-leukemia-therapy-guided-by-measurable-residu-munir-flair-2024</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/measurable-residual-disease-guided-therapy-for-chronic-lymphocyt-munir-flair-2025</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/impact-of-minimal-residual-disease-on-progression-free-survival-glow-mrd-2023</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/first-line-venetoclax-combinations-in-chronic-lymphocytic-leukem-eichhorst-cll13-2023</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/assessment-of-minimal-residual-disease-in-standard-risk-aml-npm1-ivey-npm1-2016</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/impact-of-conditioning-intensity-of-allogeneic-transplantation-f-hourigan-jco-2020</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/2021-update-on-mrd-in-acute-myeloid-leukemia-a-consensus-documen-heuser-eln-2021</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/measurable-residual-flt3-internal-tandem-duplication-before-allo-dillon-flt3-2024</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/gilteritinib-as-post-transplant-maintenance-for-aml-with-interna-levis-morpho-2024</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/measurable-residual-disease-and-posttransplantation-gilteritinib-levis-mrd-gilteritinib-2</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/postinduction-molecular-mrd-identifies-patients-with-npm1-aml-wh-othman-npm1-2024</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-measurements-as-early-outcome-predictors-i-kurtz-jco-2018</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/remission-assessment-by-circulating-tumor-dna-in-large-b-cell-ly-roschewski-jco-2025</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/prospective-validation-of-circulating-tumor-dna-measurable-resid-wang-hovon902-2026</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/interim-assessment-by-circulating-tumor-dna-in-primary-mediastin-camus-lysa-pmbcl-2026</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-assessment-of-disease-response-in-large-b-stepan-transform-ctdna-2</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/detection-and-surveillance-of-bladder-cancer-using-urine-tumor-d-dudley-2019-ucappseq</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/detection-and-diagnostic-utilization-of-cellular-and-cell-free-t-dudley-diehn-2021-review</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/an-ultrasensitive-method-for-detection-of-cell-free-rna-nesselbush-2025-rareseq-</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/urine-cell-free-rna-analysis-for-bladder-cancer-detection-and-mo-liu-aacr-2025-3773</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/urine-cell-free-rna-for-bladder-cancer-detection-and-treatment-r-liu-natmed-2026-urareseq</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/field-effect-informed-urine-liquid-biopsy-for-bladder-cancer-shi-cell-2026-field</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/perioperative-durvalumab-with-neoadjuvant-chemotherapy-in-operab-niagara-nejm-2024</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/circulating-tumor-dna-ctdna-in-patients-with-mibc-who-received-p-niagara-ctdna-asco-2025-</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/urinary-tumor-dna-utdna-and-circulating-tumor-dna-ctdna-in-patie-niagara-utdna-asco-gu-20</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/gemcitabine-intravesical-system-plus-cetrelimab-or-cetrelimab-al-sunrise4-jco-2026</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/tar-200-for-bcg-unresponsive-high-risk-nmibc-results-from-the-ph-sunrise1-jco-2025</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/sunrise-3-tar-200-plus-cetrelimab-or-tar-200-versus-bcg-in-bcg-n-sunrise3-tip</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/erdafitinib-in-patients-with-high-and-intermediate-risk-non-musc-thor2-final-2026</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/ctdna-guided-immunotherapy-following-radical-cystectomy-for-musc-tombola-2026</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/early-detection-of-metastatic-relapse-and-monitoring-of-therapeu-christensen-jco-2019</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/urine-tumor-dna-detection-of-minimal-residual-disease-in-muscle-chauhan-2021</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/urine-cell-free-dna-multi-omics-to-detect-mrd-and-predict-surviv-chauhan-2023</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/gemcitabine-and-cisplatin-plus-nivolumab-as-organ-sparing-treatm-galsky-natmed-2023</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/monitoring-of-plasma-and-urine-tumor-derived-dna-to-inform-bladd-galsky-pnas-2026</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/clinical-efficacy-and-biomarker-analysis-of-neoadjuvant-atezoliz-abacus-2019</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/abacus-2-abacus2</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/non-invasive-detection-of-urothelial-cancer-through-the-analysis-uroseek-2018</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/urine-dna-methylation-assay-enables-early-detection-and-recurren-chen-utmema-2020</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/clinical-effectiveness-of-a-multitarget-urine-dna-test-for-uroth-wu-uiseek-2024</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/distinct-longitudinal-patterns-of-urine-tumor-dna-in-patients-un-vedeld-2024</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/elevated-t-cell-exhaustion-and-urinary-tumor-dna-levels-are-asso-strandgaard-2022</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/urine-tumor-dna-to-stratify-the-risk-of-recurrence-in-patients-t-st-laurent-2025-s1605</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/postinduction-urine-tumor-dna-is-predictive-for-response-to-main-lotan-insite-2026</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/postresection-urinary-tumor-dna-refines-residual-disease-assessm-huang-nmibc-utdna-2026</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
<url>
<loc>https://mrdwatch.com/briefings/additional-verified-2025-2026-utdna-citations-other-2025-2026-catalog</loc>
<lastmod>2026-11-18T18:39:52.799Z</lastmod>
</url>
</urlset>
